Rani Therapeutics Holdings (RANI) AI Stock Analysis

• Market Cap: $35.94M
• Dividend Yield: N/A
• Average Volume (3M): 3.16M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.66
• Revenue Growth: N/A
• EPS Growth: 20.85%
• Country: US
• Employees: 105
• Sector: Healthcare
• Sector Strength: 41
• Industry: Biotechnology
• EPS (TTM): -0.22
• Shares Outstanding: 43,591,230
• 10 Day Avg. Volume: 8,843,437
• 30 Day Avg. Volume: 3,162,497
• PEG Ratio: -0.07
• Price to Book (P/B): -4.74
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.72
• Enterprise Value/Market Cap: 0.95
• Enterprise Value/Revenue: 4.52
• Enterprise Value/Gross Profit: 67.43
• Enterprise Value/Ebitda: -0.17
• 1Y Price Target: $7.00
• Price Target Upside: 1220.75% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 32 Underperform
• Price Target: ―

Rani Therapeutics Holdings' overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.

Positive Factors

Market Potential

The obesity market is massive, with ~70M obese American adults, creating potential for multiple players and the versatility of RaniPill could enable further partnerships or internal development programs as obesity drugs come off-patent.

Product Development

Rani has demonstrated successful delivery of semaglutide via RaniPill with comparable bioavailability, weight loss, and PK, which could lead to a nearer term path to revenue in markets where semaglutide is coming off patent.

Strategic Partnerships

Rani entered into a research agreement with Chugai Pharmaceutical Co., indicating a significant collaboration.

Negative Factors

Financial Performance

Rani Therapeutics reported 1Q25 results with a net loss of ($12.7M) and ended the period with $15.9M in cash, indicating the company will require additional capital in the near term.

Funding Requirements

Rani expects its cash runway to last into 3Q25 without additional funding.

Risk Factors

Risks include, but are not limited to: negative Phase 2 data; negative clinical readouts with other candidates; failure to achieve approvals for key pipeline projects; possible partnership risk; slower-than-projected market uptake.

Rani Therapeutics Holdings Business Overview & Revenue Model

Company Description

Rani Therapeutics Holdings (RANI) is a healthcare company focused on developing innovative oral biologics utilizing its proprietary RaniPill technology. The company operates within the biotechnology and pharmaceutical sectors, offering a unique solution for the oral delivery of biologics, which are traditionally administered via injection. Rani's core product, the RaniPill capsule, is designed to deliver large-molecule drugs through the gastrointestinal tract, thereby improving patient compliance and expanding the potential market for biologic therapies.

How the Company Makes Money

Rani Therapeutics Holdings generates revenue primarily through the development and commercialization of its RaniPill technology. The company earns money by partnering with pharmaceutical companies to develop oral versions of existing injectable biologics. These partnerships often involve research and development collaborations, licensing agreements, and milestone payments. Rani may also receive royalties from the sale of drugs developed using its technology. Additionally, the company may engage in direct sales of its RaniPill technology or related products once they receive regulatory approval and enter the market.

Rani Therapeutics Holdings Financial Statement Overview

Summary

Rani Therapeutics Holdings shows weak financial performance with consistent net losses and no revenue. The balance sheet is under stress with high leverage, and cash flow issues persist, indicating significant operational and financial challenges.

Income Statement

Rani Therapeutics Holdings has consistently reported zero revenue over the past three years, indicating a lack of sales activity or product commercialization. The company has also faced persistent net losses, which have slightly improved from $63.34 million in 2022 to $30.02 million in 2024. EBIT and EBITDA margins remain negative, reflecting ongoing operational challenges.

Balance Sheet

The company's balance sheet shows a weak equity base with stockholders' equity consistently declining each year. The debt-to-equity ratio is high due to significant liabilities compared to equity, raising concerns over financial leverage. The equity ratio is low, indicating a heavy reliance on debt financing. These factors may pose financial risks if the company cannot achieve profitability or secure additional funding.

Cash Flow

Rani Therapeutics Holdings has consistently experienced negative operating and free cash flows, indicating cash burn issues. Despite some reduction in free cash flow deficits, the company still struggles to generate positive cash flow from operations. The operating cash flow to net income ratio remains negative, highlighting challenges in converting sales into cash.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.03M	0.00	0.00	2.72M	462.00K
Gross Profit	1.03M	-822.00K	-1.31M	2.72M	462.00K
EBITDA	-50.52M	-65.28M	-60.89M	-52.08M	-15.96M
Net Income	-30.02M	-33.97M	-63.34M	-53.09M	-16.70M
Balance Sheet
Total Assets	36.63M	57.92M	108.03M	124.21M	79.42M
Cash, Cash Equivalents and Short-Term Investments	27.64M	48.54M	98.48M	117.45M	73.06M
Total Debt	29.71M	30.10M	30.21M	0.00	3.77M
Total Liabilities	33.14M	32.47M	34.02M	2.64M	192.75M
Stockholders Equity	1.99M	12.87M	36.85M	47.41M	-113.34M
Cash Flow
Free Cash Flow	-35.76M	-52.47M	-48.13M	-32.75M	-16.16M
Operating Cash Flow	-35.50M	-51.24M	-46.52M	-32.24M	-14.96M
Investing Cash Flow	19.81M	29.86M	-72.44M	-506.00K	-1.20M
Financing Cash Flow	13.59M	233.00K	29.00M	77.15M	72.68M

Rani Therapeutics Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.53
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RANI, the sentiment is Neutral. The current price of 0.53 is above the 20-day moving average (MA) of 0.52, below the 50-day MA of 0.55, and below the 200-day MA of 1.37, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 50.23 is Neutral, neither overbought nor oversold. The STOCH value of 44.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RANI.

Rani Therapeutics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	kr5.63B	10.40	-63.86%	1.96%	27.11%	26.73%
TCRX	52 Neutral	$109.22M	―	-78.93%	―	-70.15%	―
IGMS	46 Neutral	$76.35M	―	-245.59%	―	27.36%	23.82%
ADAG	44 Neutral	$93.75M	―	-55.14%	―	-99.43%	-69.40%
ADVM	44 Neutral	$56.40M	―	-127.99%	―	―	37.54%
CRBP	43 Neutral	$113.31M	―	-44.89%	―	―	64.71%
RANI	32 Underperform	$35.94M	―	-1372.59%	―	―	20.85%

Rani Therapeutics Holdings Corporate Events

Rani Therapeutics Board Restructures After DeBuono’s Retirement

On April 24, 2025, Laureen DeBuono retired from the Board of Directors of Rani Therapeutics Holdings, Inc., with her decision not stemming from any disagreements with the company. Her departure led to a reconstitution of the Board’s committees, with new chairs and members appointed to the Audit, Compensation, and Nominating and Corporate Governance Committees.

Spark’s Take on RANI Stock

According to Spark, TipRanks’ AI Analyst, RANI is a Underperform.

Rani Therapeutics Holdings’ overall stock score reflects significant financial struggles with no revenue and consistent net losses. The technical analysis shows a bearish trend, and the valuation is challenging with a negative P/E ratio. Strategic advancements in technology and potential partnerships are positive but are overshadowed by financial constraints and high leverage.

To see Spark’s full report on RANI stock, click here.